# Eli Lilly and Company: Phase 4 study completed, 233 enrolled (Atopic Dermatitis)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Eli Lilly and Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden |
| NCT ID | NCT07006792 |
| Phase | Phase 4 |
| Status | completed |
| Conditions | Atopic Dermatitis |
| Intervention types | drug |
| Target enrollment | 233 |
| Site countries | United States, Argentina, Brazil, Canada, Puerto Rico |
| Posted | 2025-06-05 |
| Planned start | 2025-06-16 |
| Event | Completed |
| Event date | 2026-09-21 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- 233 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07006792). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.